Helix B surface peptide is cardio-protective through inhibition on myocardial apoptosis induced by ischemia/reperfusion injury
Background Erythropoietin (EPO), a well-known hematopoietic cytokine, is widely used for the treatment of anemia.Recently studies in vitro and in vivo demonstrated that EPO also has tissue-protective properties including heart.However the prospect of EPO was shadowed because of the character of stimulating erythropoiesis, which may enhance the risk of patients with cardiovascular diseases.A small peptide which mimicked the 3D structure of EPO, termed helix B surface peptide (HBSP), was developed and shown to be neuro-protective similiar with EPO but did not increase RBC,hematocrit or platelet count.Further study proved that HBSP also protected kidney against ischemia/reperfusion injury.
JIANG Na GUO Wen-yi SI Rui
Department of Cardiology,Xijing Hospital,Fourth Military Medical University,Xi”an,China
国内会议
北京
英文
180-181
2013-03-20（万方平台首次上网日期，不代表论文的发表时间）